<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110911">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849965</url>
  </required_header>
  <id_info>
    <org_study_id>DSC127-2012-02</org_study_id>
    <nct_id>NCT01849965</nct_id>
  </id_info>
  <brief_title>Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers</brief_title>
  <acronym>STRIDE 2</acronym>
  <official_title>A Randomized, Double-Blind, Parallel-group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derma Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Derma Sciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if DSC127 is effective in increasing incidence of complete wound closure up to
      10 weeks confirmed 2 weeks later, compared with vehicle (gel without active ingredient) and
      compared with a standard-of-care gel, in subjects with diabetes mellitus (DM) who have
      chronic Wagner Grade 1 or 2 diabetic foot ulcers, 0.75 - 6cm2 in size.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo a two week screening period to assess plantar ulcer healing, and those
      healing less than 30% will be eligible for randomization providing all other criteria are
      met.  Four weeks of &quot;blinded&quot; randomized treatment follows the screening period, and an
      observation period of six weeks follows the treatment period.  If the ulcer closes during
      the observation period a visit two weeks later is required to confirm complete closure, and
      at this time the subjects enters a durability assessment period of up to 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed 2 weeks later) after initiation of treatment.</measure>
    <time_frame>Target ulcer must achieve complete wound closure by 10 weeks post first treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary endpoint of complete closure is assessed by the Principle Investigator at the site; ulcer measurements are calculated via tracings submitted to the Canfield system, and photographs are collected as confirmation of closure via the Canfield system.  Assessment of DSC127 vs vehicle control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed two weeks later) after initiation of treatment.</measure>
    <time_frame>Target ulcer must achieve complete wound closure by 10 weeks post first treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary endpoint of complete closure is assessed by the Principle Investigator at the site; ulcer measurements are calculated via tracings submitted to the Canfield system, and photographs are collected as confirmation of closure via the Canfield system. Assessment of DSC127 vs Standard of Care control.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to the visit where the target ulcer achieves confirmed complete wound closure</measure>
    <time_frame>Measurements to ten weeks post first dose</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent reduction in target ulcer area per week.</measure>
    <time_frame>Up to ten weeks post first dose</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of and time to target ulcer recurrence after confirmed complete wound closure has been established.</measure>
    <time_frame>To a maximum of 24 weeks post first dose</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">633</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>DSC127</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel comprising HEC with parabens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aquasite gel, as standard of care gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSC127</intervention_name>
    <description>DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.</description>
    <arm_group_label>DSC127</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo vehicle gel</intervention_name>
    <arm_group_label>Vehicle gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care gel, Aquasite</intervention_name>
    <arm_group_label>Standard of Care gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ambulatory subject age ≥18 years at the time of informed consent

          -  Has type 1 or type 2 DM under metabolic control as confirmed by a glycosylated
             hemoglobin (HbA1c) of ≤12% and a serum creatinine level of ≤3mg/dL

          -  At Screening, subject has at least one ulcer that fulfills all of the following
             criteria:

               -  present for ≥1 month and ≤1 year

               -  Partial- or full- thickness and not involving bone, tendon, or capsule (probing
                  to tendon or capsule), i.e. Wagner Grade 1 or 2.

               -  Has no sign of infection or osteomyelitis

               -  Plantar neuropathic ulcer - predominately be on the plantar surface (i.e. weight
                  bearing) of the foot to ensure adequate off-loading.

               -  Size of the target ulcer must be 0.75-6 cm2.

               -  Target ulcer must be non-healing as defined as &lt;30% reduction in area in
                  response to standard of care during the Screening Period

                    -  If more than one ulcer is present that meets the inclusion criteria, the
                       largest one will be considered the target ulcer

                    -  Non-target ulcers will also be treated according to standard of care
                       (Acute Charcot Neuroarthropathy of the foot with the target ulcer must be
                       excluded)

          -  An ankle brachial index (ABI) &gt;0.7 on the foot with the target ulcer.

          -  An assessment of the baseline level of neuropathy of the foot using Semmes-Weinstein
             filaments.

          -  A female subject of childbearing potential must have a negative serum pregnancy test
             at the time of Screening.

          -  A female subject of childbearing potential must be willing to use a medically
             acceptable method of birth control, such as Essure®, hormonal contraception (oral
             pills, implantable device, or skin patch), intrauterine device, tubal ligation, or
             double barrier throughout the study.  A female subject of childbearing potential who
             practices abstinence is not required to employ birth control.

          -  Has the ability and willingness to understand and comply with study procedures and to
             give written informed consent prior to enrollment in the study or initiation of study
             procedures

        Exclusion Criteria:

          -  Has a known hypersensitivity to any of the investigational drug or vehicle or
             standard of care gel components

          -  Has been exposed to any investigational agent within 30 days of entry into the study

          -  A female who is pregnant or nursing

          -  Has active malignant disease of any kind. A subject, who has had a malignant disease
             in the past, was treated and is currently disease-free, may be considered for study
             entry.

          -  Has a history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome)

          -  Has a hemoglobin of less than 10 gm/dL.

          -  Has chronic liver dysfunction evidenced by transaminase levels greater than 2 ×
             normal

          -  Is receiving hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) therapy

          -  Has had prior radiation therapy to any part of the foot with the target ulcer under
             study

          -  Current use of corticosteroids and immunosuppressants (within the past 8 weeks)

          -  Has an ulcer  primarily ischemic in etiology

          -  Has sickle-cell anemia, Reynaud's, or peripheral vascular disease

          -  Has received a biologic agent, growth factor, or skin equivalents (Regranex®,
             Apligraft, or Dermagraft), in the past 30 days

          -  Has a target ulcer which is determined to be clinically infected and requires topical
             antimicrobials or agents known to affect wound healing. Any antibiotic therapy must
             be completed or discontinued at Screening.

          -  Has a Wagner Grade 3 or higher DFU, deep abscess, or gangrene

          -  Has a baseline blood pressure (BP) reading &gt;160 systolic and/or &gt;90 diastolic mmHg.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gere S diZerega, MD</last_name>
    <role>Study Director</role>
    <affiliation>Derma Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelagh Verco, PhD</last_name>
    <phone>805-704-1179</phone>
    <email>sverco@dermasciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meredith Landau</last_name>
    <phone>609-514-4744</phone>
    <phone_ext>1150</phone_ext>
    <email>mlandau@dermasciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Heart Institute, c/o Research Dept</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Vigliotti</last_name>
      <phone>602-266-2200</phone>
      <phone_ext>2222</phone_ext>
      <email>lvigliotti@abrazohealth.com</email>
    </contact>
    <investigator>
      <last_name>Julio Rodriguez-Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precision Trials</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari Alexander</last_name>
      <phone>509-808-4522</phone>
      <email>mari@precisiontrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Margaux Steinbach</last_name>
      <phone>602-931-4507</phone>
      <phone_ext>221</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Michael Sekosky, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Foot &amp; Ankle Specialists, PC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mya Hernandez</last_name>
      <phone>602-274-4100</phone>
    </contact>
    <investigator>
      <last_name>Arthur Tallis, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Burn Center Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Schein</last_name>
      <phone>602-344-1342</phone>
      <email>renee-robles-schein@dmgaz.org</email>
    </contact>
    <investigator>
      <last_name>Bryan Roth, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ledesma Foot and Ankle</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wallace</last_name>
      <phone>520-245-7379</phone>
      <email>r.wallace@atlantishg.com</email>
    </contact>
    <investigator>
      <last_name>Paul Ledesma, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Fort Smith Clinical Research</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Hyde</last_name>
      <email>Cheryl.hyde@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Delilah Easom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trovare Clinical Research, Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Riddick</last_name>
      <phone>661-663-3096</phone>
      <email>sriddick@trovareclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>John Zimmerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Technologies, LLC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Morfin</last_name>
      <phone>323-264-6187</phone>
      <email>francis_morfin@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gabriel Halperin, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samuel Merritt University, California School of Podiatric Medicine</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Edmunds</last_name>
      <phone>510-869-6511</phone>
      <phone_ext>5629</phone_ext>
      <email>kedmunds@samuelmerritt.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Dutra, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Health Clinic</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Griffith</last_name>
      <phone>909-562-0255</phone>
      <email>bgriffith@trialogic.com</email>
    </contact>
    <investigator>
      <last_name>Elliot Meltzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayana Sarkisova</last_name>
      <phone>415-680-0871</phone>
      <email>gsarkisova@ccrmail.net</email>
    </contact>
    <investigator>
      <last_name>Alexander Reyzelman, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopedic Research Associates</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>72903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Ramos</last_name>
      <email>heidiramos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Hansen, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tellus Clinical Research, Inc.</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Analay Rico</last_name>
      <phone>786-409-2011</phone>
      <email>arico@tellusclinical.com</email>
    </contact>
    <investigator>
      <last_name>Martin Valdes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzmed Clinical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Mallada</last_name>
      <email>lmallada@luzmedcr.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Padron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reserach in Miami, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlando Sanchez</last_name>
      <phone>305-889-6670</phone>
      <email>osanchez@researchinmiami.com</email>
    </contact>
    <investigator>
      <last_name>Adam Ringler, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Valdes</last_name>
      <email>teresavaldes_pmr@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Oscar Barretto, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivette Lopez</last_name>
      <phone>305-220-2727</phone>
      <email>ilopez@advancedparmacr.com</email>
    </contact>
    <investigator>
      <last_name>Gilbert Weiner, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Phase Clincal Trials, Inc.</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Gonzalez</last_name>
      <phone>305-858-4300</phone>
      <email>lourdes.gonzalez@newphaseclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Lesley Anne Warren, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SouthEast Medical Centre</name>
      <address>
        <city>Park</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Apelbaum, MD</last_name>
      <phone>954-202-5137</phone>
      <email>mapelbaum@invesclinic.com</email>
    </contact>
    <investigator>
      <last_name>Rene Casanova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Miami Clinical Research</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Deleon</last_name>
      <phone>305-667-4697</phone>
      <email>tdeleon@smcresearch.net</email>
    </contact>
    <investigator>
      <last_name>Julian Naranjo, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aiyan Diabetes Center</name>
      <address>
        <city>Evans</city>
        <state>Georgia</state>
        <zip>30809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Balan Sivakumar</last_name>
      <phone>706-868-0320</phone>
      <email>chola_jk@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Janaki Nadarajah, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials</name>
      <address>
        <city>Blackfoot</city>
        <state>Idaho</state>
        <zip>83221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casica Saunders-Kmetz</last_name>
      <phone>208-643-0006</phone>
      <email>ekmetzect@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paul Beckett, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital and Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Davis</last_name>
      <phone>312-567-2601</phone>
      <email>aldavis@mercy-chicago.org</email>
    </contact>
    <investigator>
      <last_name>George Enriquez, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James A Lovell Federal Health Care Center</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Nyland</last_name>
      <phone>224-610-1310</phone>
      <email>nyland.jill@va.gov</email>
    </contact>
    <investigator>
      <last_name>William Chagares, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Wound Center</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan James, RN</last_name>
      <phone>812-353-2828</phone>
      <email>SJames5@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jodie Harper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Center</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Seale</last_name>
      <phone>765-216-6218</phone>
      <email>tara.seale@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Matthew DeWitt, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Wheeler</last_name>
      <phone>316-838-7700</phone>
      <email>cwheeler@prnofkansas.com</email>
    </contact>
    <investigator>
      <last_name>Jeremy Tamir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bluegrass Foot Center c/o Research Concierge, LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie English</last_name>
      <phone>270-313-2110</phone>
      <email>denglish.research@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Steven Block, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grace Research</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Maranto</last_name>
      <phone>318-638-7309</phone>
      <email>amaranto.grace@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Susan Kemp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center, Division of Podiatry</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Borland</last_name>
      <phone>617-632-8420</phone>
      <email>cborland@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Thanh Dinh, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shauneen Valliere, NP</last_name>
      <phone>508-856-1767</phone>
      <email>Shauneen.Valliere@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Louis Messina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medex Research Institute</name>
      <address>
        <city>Caro</city>
        <state>Michigan</state>
        <zip>48723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waqar Mian</last_name>
      <phone>410-972-5956</phone>
      <email>mcdoctor1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Naveed Mahfooz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Center for Clinical Trials</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Forbes</last_name>
      <phone>248-352-2228</phone>
      <email>aforbes.acct@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Harry Kezelain, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Development Associates, LLC</name>
      <address>
        <city>Rosedale</city>
        <state>New York</state>
        <zip>11422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Anne Fable</last_name>
      <phone>718-276-4750</phone>
      <email>mafable@clinicalresearchdevelopment.org</email>
    </contact>
    <investigator>
      <last_name>David Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury, LLC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Thompson</last_name>
      <phone>704-647-9913</phone>
      <email>sthompson@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>James Mazur, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Infectious Disease &amp; Infusion Center Inc.</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janis Southerly</last_name>
      <phone>419-228-1535</phone>
      <email>janis.sutherly@nobadbugs.com</email>
    </contact>
    <investigator>
      <last_name>Ravi Kamepalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSU Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Patterson</last_name>
      <email>melissa.patterson@okstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Willmann</last_name>
      <email>nancy.willmann@okstate.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Rock, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunstone Medical Research, LLC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>95704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constance Clark</last_name>
      <phone>541-646-7615</phone>
      <email>constancec@sunstoneresearch.com</email>
    </contact>
    <investigator>
      <last_name>James Holdermann, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blair Medical Associates, Inc.</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Benton</last_name>
      <phone>814-946-7569</phone>
      <email>jbenton@ma.md</email>
    </contact>
    <investigator>
      <last_name>Harry Penny, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keyston Medical Research Associates, LLC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Callie Brown</last_name>
      <phone>610-997-0408</phone>
      <email>Aidlia@ptd.net</email>
    </contact>
    <investigator>
      <last_name>Brent Bernstein, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Clinic</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazal Routh</last_name>
      <phone>215-560-7330</phone>
      <email>rekharouth@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Parish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin Foot &amp; Ankle</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Brenneman</last_name>
      <phone>717-757-3537</phone>
      <phone_ext>7101</phone_ext>
      <email>clease@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Maria Kasper, DPM, FACFAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Shain</last_name>
      <email>LShain3@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Fitzgerald, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Texas Podiatric Medicine &amp; Surgery</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Warner</last_name>
      <phone>214-369-7400</phone>
      <phone_ext>1</phone_ext>
      <email>rwarner@limbsalvagecentre.com</email>
    </contact>
    <investigator>
      <last_name>Leon Brill, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bone and Joint Institute</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della Weiss</last_name>
      <phone>817-735-2054</phone>
      <email>della.weis@unthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Travis Motley, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Foot &amp; Ankle Specialists</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Vilchis</last_name>
      <phone>713-777-5343</phone>
      <email>Monica@mercurycr.us.com</email>
    </contact>
    <investigator>
      <last_name>Gabriel Maislos, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Redwood Health Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylynn Shakespear</last_name>
      <phone>801-213-4043</phone>
      <email>Kaylynn.shakespear@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Rushton, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Kuzyk, RN</last_name>
      <email>lkuzyk@hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>John Embil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mayer Institute</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8R 2R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Roth-Albin</last_name>
      <email>roth.ivana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Perry Mayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audra Vair</last_name>
      <email>audra.vair@sjhc.london.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ian Holloway</last_name>
      <email>ian.holloway@sjhc.london.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>David Keast, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Regional Wound Healing Clinic</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4Y 1A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Coutts</last_name>
      <email>patcoutts@rogers.com</email>
    </contact>
    <investigator>
      <last_name>R. Gary Sibbald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synapta Clinical Research Centre</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelly Narrainsammy</last_name>
      <email>synaptaresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Naeem Siddique</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flamco Clinical Trials</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Phillips</last_name>
      <email>roxannepcrc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shiroma Bennimahadeo</last_name>
      <email>shiromabcrc@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Visvakuren Naidoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brookedale Clinical Research Centre</name>
      <address>
        <city>Phoenix</city>
        <state>KwaZulu Natal</state>
        <zip>4068</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aadila Sacoor</last_name>
      <email>aadilasacoor@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nazreen Kader</last_name>
      <email>Nazreenkader786@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammed Sacoor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Randles Road Medical Centre</name>
      <address>
        <city>Durban</city>
        <state>ZwaZulu Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Bhagowat</last_name>
      <email>rmctrials@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Amina Jhazbhay</last_name>
      <email>ajhazbhay@live.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Uttam Govind</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic foot ulcers</keyword>
  <keyword>Wagner Grade 1 or 2 ulcers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
